CliffBio
small molecule

TALICIA

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

Loss of exclusivityMay 2042latest FDA-listed patent expiry
CompanyTALICIA HOLDINGS INC

Drug detail

Brand nameTALICIA
Active ingredientAMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN
Strength250MG;EQ 10MG BASE;12.5MG
Dosage formCAPSULE, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2019
Marketing statusRX

Listed patents

PatentExpiresType
11878011May 2042use U-3816
9498445February 2034product
9050263February 2034product
9603806February 2034product
11135172February 2034product
11931463February 2034product
10238606February 2034product

Regulatory exclusivity

CodeExpires
GAINNovember 2027
NPNovember 2022

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.